Table 2.

Multivariate Cox regression analyses

ESRD occurrenceCrude Hazard ratio, 95% CI, and P-valueAdjusted for confounders, gender, and systolic BP Hazard ratio, 95% CI, and P-value
Phosphate (1 mg/dl)3.30 (2.46–4.43), P < 0.0011.84 (1.27–2.67), P = 0.001
Treatment with Ramipril (0 = no; 1 = yes)0.48 (0.29–0.79), P = 0.004
Albumin (1 g/dl)0.43 (0.26–0.73), P = 0.002
Hemoglobin (1 g/dl)0.90 (0.78–1.02), P = 0.11
Iohexol GFR (1 ml/min/1.73m2)0.94 (0.92–0.96), P < 0.001
Urinary Protein (1 g/24 h)1.11 (1.02–1.21), P = 0.01
Gender (0 = M; 1 = F)1.71 (0.94–3.10), P = 0.08
Systolic pressure (1 mmHg)1.03 (1.01–1.04), P = 0.001
Combined end point (ESRD/creatinine doubling)Crude Hazard ratio, 95% CI, and P-valueAdjusted for confounders, gender, and systolic BP Hazard ratio, 95% CI, and P-value
Phosphate (1 mg/dl)2.87 (2.18–3.77), P < 0.0011.66 (1.18–2.33), P = 0.004
Treatment with Ramipril (0 = no; 1 = yes)0.49 (0.31–0.79), P = 0.003
Albumin (1 g/dl)0.50 (0.31–0.82), P = 0.006
Hemoglobin (1 g/dl)0.92 (0.81–1.05), P = 0.20
Iohexol GFR (1 ml/min/1.73m2)0.95 (0.93–0.97), P < 0.001
Urinary protein (1 g/24 h)1.11 (1.02–1.20), P = 0.01
Gender (0 = M; 1 = F)1.51 (0.87–2.63), P = 0.14
Systolic pressure (1 mmHg)1.02 (1.01–1.03), P = 0.002
  • The approach to multivariate Cox's regression analysis is described in detail in the Methods section. Data are expressed as hazard ratio, 95% CI, and P-values.